Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0E8ZY
|
||||
| Former ID |
DIB007692
|
||||
| Drug Name |
Vapitadine
|
||||
| Synonyms |
Hivenyl; Vapitadine dihydrochloride; R-129160; Vapitadine (oral), Barrier Therapeutics
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Allergic skin disorders [ICD10:L00-L99] | Phase 2 | [1] | ||
| Company |
Barrier Therapeutics Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C17H20N4O
|
||||
| Canonical SMILES |
c12n(c(cn1)C(=O)N)CCc1c(C32CCNCC3)cccc1
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Histamine H1 receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| PANTHER Pathway | Histamine H1 receptor mediated signaling pathway | ||||
| Reactome | Histamine receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| IL-4 Signaling Pathway | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020866) | ||||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020866) | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.